Attached files

file filename
EX-23.1 - Hancock Jaffe Laboratories, Inc.ex23-1.htm
EX-10.41 - Hancock Jaffe Laboratories, Inc.ex10-41.htm
EX-10.40 - Hancock Jaffe Laboratories, Inc.ex10-40.htm
EX-10.39 - Hancock Jaffe Laboratories, Inc.ex10-39.htm
EX-10.38 - Hancock Jaffe Laboratories, Inc.ex10-38.htm
EX-4.10 - Hancock Jaffe Laboratories, Inc.ex4-10.htm
EX-4.9 - Hancock Jaffe Laboratories, Inc.ex4-9.htm
EX-4.7 - Hancock Jaffe Laboratories, Inc.ex4-7.htm
EX-3.6 - Hancock Jaffe Laboratories, Inc.ex3-6.htm
EX-1.1 - Hancock Jaffe Laboratories, Inc.ex1-1.htm
S-1/A - Hancock Jaffe Laboratories, Inc.forms-1a.htm

 

AMENDMENT TO SECURITIES PURCHASE AGREEMENT

 

This Amendment to Securities Purchase Agreement (this “Amendment”), dated as of December 29, 2017, is by and among Hancock Jaffe Laboratories, Inc., a Delaware corporation (the “Company”), and the undersigned signatories hereto (collectively, the “Lenders”) and amends that certain Securities Purchase Agreement (the “Purchase Agreement”), Senior Secured Convertible Note (the “Notes”), and Common Stock Purchase Warrant (the “Warrants”), by and among the Company and the signatories thereto (the “Purchasers” and altogether, the “Transaction Documents”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in the Transaction Documents.

 

RECITALS

 

WHEREAS, the Company and the Lenders desire to amend the Transaction Documents to extend the maturity date of the Notes to February 28, 2018;

 

WHEREAS, the Company and the Lenders desire to amend Transaction Documents to provide that the number of Warrant Shares exercisable under the Warrants shall equal 75% of the number of shares of Common Stock issuable upon conversion of the Notes;

 

WHEREAS, the Company and the Lenders desire to amend the Transaction Documents to eliminate the increase of the Principal Amount and number of shares issuable upon exercise of the Warrants upon an Event of Default;

 

WHEREAS, the Company and the Lenders desire to defer any accrued interest payable under the Notes to January 11, 2018;

 

WHEREAS, pursuant to Section 5.5 of the Purchase Agreement, the Transaction Documents may be amended or its terms waived with the written consent of the Company and the Purchasers holding a majority of the aggregate principal amount of all Notes issued under the Purchase Agreement (the “Requisite Holders”); and

 

WHEREAS, the Company and the undersigned Lenders, constituting the Requisite Holders, desire to amend the Transaction Documents as hereinafter set forth.

 

AGREEMENT

 

NOW, THEREFORE, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged and agreed, the parties hereby agree as follows:

 

1. Amendment to Purchase Agreement Section 2.2(a)(iii). Section 2.2(a)(iii) of the Purchase Agreement is hereby amended and restated in its entirety as follows:

 

“(iii) a Warrant registered in the name of such Purchaser with an exercise price per share equal to the lesser of (a) $14.40 or (b) 120% of the Conversion Price, and to purchase up to a number of Common Shares equal to 75% of the number of Common Shares issuable upon conversion of such Purchaser’s Note.”

 

   

 

 

2. Amended and Restated Note. In connection and to facilitate the stated intent of the Company and the Lenders in the recitals, among other things, the parties consent and agree that the Notes issued to all Purchasers are hereby amended and restated, substantially in the form attached hereto as Exhibit A (the “Amended and Restated Note”). The Company shall execute and deliver the Note to each Purchaser.

 

3. Amended and Restated Warrant. In connection and to facilitate the stated intent of the Company and the Lenders in the recitals, among other things, the parties consent and agree that the Warrants issued to all Purchasers are hereby amended and restated substantially in the form attached hereto as Exhibit B (the “Amended and Restated Warrant”). The Company shall execute and deliver the Warrant to each Purchaser.

 

4. No Other Amendments. Except as herein amended, all provisions of the Transaction Documents shall remain in full force and effect.

 

5. Governing Law. This Amendment shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware.

 

6. Enforceability. If any provision of this Amendment is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Amendment will remain in full force and effect. Any provision of this Amendment held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

 

7. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall have the same force and effect of the original.

 

[Signature Page Follows]

 

   

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first above written.

 

  COMPANY:
   
  HANCOCK JAFFE LABORATORIES, INC.
     
  By: /s/ William Abbott
  Name: William Abbott
  Title: Chief Financial Officer
     
  LENDER:
     
  By:                     
  Name:  
  Title:  

 

Signature Page to Amendment to Securities Purchase Agreement

 

   

 

 

EXHIBIT A

 

Amended and Restated Note

 

Exhibit to Amendment to Securities Purchase Agreement

 

   

 

 

EXHIBIT B

 

Amended and Restated Warrant

 

Exhibit to Amendment to Securities Purchase Agreement